Compare Futu Holdings Ltd (FUTU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? Futu Holdings Ltd trades at $105.6 (market cap $15.24B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.7× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.39% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FUTU | VRTX | |
|---|---|---|
Market Cap | $15.24B | $132.79B |
Sector | Financials | Health |
52-Week High | $199.04 | $529.59 |
52-Week Low | $89.76 | $374.46 |
Enterprise Value | $15.09B | $126.92B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings Limited (FUTU) trades at $109.02, up 4.31% today, with a bullish technical signal from moving averages and strong support at $106. The company reported robust 2025 revenue of $22.85 billion and net income of $11.34 billion, with a high net margin of 49.62%. Valuation ratios appear reasonable, with a P/E of 12.07 and P/S of 5.05. However, recent earnings misses in Q1 2026 and a securities class action lawsuit deadline on August 25, 2026, introduce near-term uncertainty.
The outlook for FUTU is mixed: strong profitability and analyst buy ratings (58% consensus) support upside, but legal risks and earnings volatility pose challenges. Investors should weigh solid fundamentals against regulatory and litigation headwinds, with technical levels suggesting $111 as immediate resistance.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
